title: Heath-related quality of life in thyroid cancer patients following radioiodine ablation.
abstract: BACKGROUND
  There is limited information about the medium to long-term health-related quality of life (QOL) in thyroid cancer patients after initial therapy and the existing studies suffer from limitations. The aim of the study was to assess the determinants of medium-term QOL after the initial therapy.
  
  
  METHODS
  Following a total thyroidectomy, 88 thyroid cancer patients received either rhTSH or hypothyroid-assisted radioiodine ablation (RRA) using 3.7 GBq (100 mCi) of radioiodine. QOL evaluation of the patients using the validated Functional Assessment of Chronic Illness & Therapy (FACIT) was performed at the time of inclusion (t0) and later at the 9-month post-RRA (t1).
  
  
  RESULTS
  83 patients were eligible for the final evaluation. Medium-term FACIT scores were not statistically different between t0 and t1 patients. All but one domain of the QOL score was similar between t0 and t1. Using a multivariate analysis, only age and immediate postoperative QOL scores were found to be determinants of the overall medium term 9-month QOL scores. Analysis showed that 'high QOL levels' (baseline and 9-month) and 'no depression', 'low anxiety levels', were associated with '<45 yrs', 'men', 'partner', and 'rhTSH stimulation'.
  
  
  CONCLUSIONS
  The use of radioiodine ablation does not seem to affect the medium term QOL scores of patients. Medium-term QOL is mainly determined by pre-ablation QOL. The assessment of baseline QOL might be interesting to evaluate in order to adapt the treatment protocols, the preventive strategies, and medical information to patients for potentially improving their outcomes.
authors.affiliation: Service central de Biophysique et de Médecine Nucléaire, centre hospitalo-universitaire de Timone, 264 rue Saint-Pierre 13385 Marseille Cedex 5, France. david.taieb@ap-hm.fr
authors.forename: David
authors.initials: D
authors.lastname: Taïeb
authors.forename: Karine
authors.initials: K
authors.lastname: Baumstarck-Barrau
authors.forename: Frédéric
authors.initials: F
authors.lastname: Sebag
authors.forename: Cécile
authors.initials: C
authors.lastname: Fortanier
authors.forename: Catherine
authors.initials: C
authors.lastname: De Micco
authors.forename: Anderson
authors.initials: A
authors.lastname: Loundou
authors.forename: Pascal
authors.initials: P
authors.lastname: Auquier
authors.forename: Fausto F
authors.initials: FF
authors.lastname: Palazzo
authors.forename: Jean-françois
authors.initials: JF
authors.lastname: Henry
authors.forename: Olivier
authors.initials: O
authors.lastname: Mundler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006304:Health Status; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012959:Socioeconomic Factors; D013964:Thyroid Neoplasms / Q000503:physiopathology* / Q000523:psychology / Q000628:therapy*; D013965:Thyroidectomy; D013972:Thyrotropin / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007457:Iodine Radioisotopes; D013972:Thyrotropin